Overlapping Molecular Pathways Leading to Autism Spectrum Disorders, Fragile X Syndrome, and Targeted Treatments

被引:0
|
作者
Maria Jimena Salcedo-Arellano
Ana Maria Cabal-Herrera
Ruchi Harendra Punatar
Courtney Jessica Clark
Christopher Allen Romney
Randi J Hagerman
机构
[1] University of California Davis School of Medicine,Department of Pediatrics
[2] UC Davis School of Medicine,Department of Pathology and Laboratory Medicine
[3] University of California Davis,Medical Investigation of Neurodevelopmental Disorders (MIND) Institute UCDHS
[4] Universidad del Valle,Group on Congenital Malformations and Dysmorphology, Faculty of Health
来源
Neurotherapeutics | 2021年 / 18卷
关键词
Autism spectrum disorders; fragile X syndrome; targeted treatments; Wnt; retinoic acid; mTOR; ERK/MAPK; signaling cross talk; endocannabinoid system; neurodevelopmental disorders;
D O I
暂无
中图分类号
学科分类号
摘要
Autism spectrum disorders (ASD) are subdivided into idiopathic (unknown) etiology and secondary, based on known etiology. There are hundreds of causes of ASD and most of them are genetic in origin or related to the interplay of genetic etiology and environmental toxicology. Approximately 30 to 50% of the etiologies can be identified when using a combination of available genetic testing. Many of these gene mutations are either core components of the Wnt signaling pathway or their modulators. The full mutation of the fragile X mental retardation 1 (FMR1) gene leads to fragile X syndrome (FXS), the most common cause of monogenic origin of ASD, accounting for ~ 2% of the cases. There is an overlap of molecular mechanisms in those with idiopathic ASD and those with FXS, an interaction between various signaling pathways is suggested during the development of the autistic brain. This review summarizes the cross talk between neurobiological pathways found in ASD and FXS. These signaling pathways are currently under evaluation to target specific treatments in search of the reversal of the molecular abnormalities found in both idiopathic ASD and FXS.
引用
收藏
页码:265 / 283
页数:18
相关论文
共 50 条
  • [1] Overlapping Molecular Pathways Leading to Autism Spectrum Disorders, Fragile X Syndrome, and Targeted Treatments
    Salcedo-Arellano, Maria Jimena
    Cabal-Herrera, Ana Maria
    Punatar, Ruchi Harendra
    Clark, Courtney Jessica
    Romney, Christopher Allen
    Hagerman, Randi J.
    NEUROTHERAPEUTICS, 2021, 18 (01) : 265 - 283
  • [2] Regulation of molecular pathways in the Fragile X Syndrome: insights into Autism Spectrum Disorders
    Silvia De Rubeis
    Claudia Bagni
    Journal of Neurodevelopmental Disorders, 2011, 3 : 257 - 269
  • [3] Regulation of molecular pathways in the Fragile X Syndrome: insights into Autism Spectrum Disorders
    De Rubeis, Silvia
    Bagni, Claudia
    JOURNAL OF NEURODEVELOPMENTAL DISORDERS, 2011, 3 (03) : 257 - 269
  • [4] Fragile X: Leading the way for targeted treatments in autism
    Lulu W. Wang
    Elizabeth Berry-Kravis
    Randi J. Hagerman
    Neurotherapeutics, 2010, 7 : 264 - 274
  • [5] Fragile X: Leading the Way for Targeted Treatments in Autism
    Wang, Lulu W.
    Berry-Kravis, Elizabeth
    Hagerman, Randi J.
    NEUROTHERAPEUTICS, 2010, 7 (03) : 264 - 274
  • [6] Targeted treatments in autism and fragile X syndrome
    Gurkan, C. Kagan
    Hagerman, Randi J.
    RESEARCH IN AUTISM SPECTRUM DISORDERS, 2012, 6 (04) : 1311 - 1320
  • [7] Molecular Mechanisms of Synaptic Dysregulation in Fragile X Syndrome and Autism Spectrum Disorders
    Telias, Michael
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2019, 12
  • [8] Aripiprazole in autism spectrum disorders and fragile X syndrome
    Craig A. Erickson
    Kimberly A. Stigler
    David J. Posey
    Christopher J. McDougle
    Neurotherapeutics, 2010, 7 : 258 - 263
  • [9] Targeted treatments in fragile X syndrome
    Hare, Emma B.
    Hagerman, Randi J.
    Lozano, Reymundo
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (06): : 531 - 543
  • [10] Aripiprazole in Autism Spectrum Disorders and Fragile X Syndrome
    Erickson, Craig A.
    Stigler, Kimberly A.
    Posey, David J.
    McDougle, Christopher J.
    NEUROTHERAPEUTICS, 2010, 7 (03) : 258 - 263